Crinetics Pharmaceuticals, Inc, a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone858-450-6464
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.43 million
Profitability
Miscellaneous
Employees47
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable
Crinetics Pharmaceuticals (NASDAQ:CRNX) Frequently Asked Questions
What is Crinetics Pharmaceuticals' stock symbol?
Crinetics Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRNX."
How were Crinetics Pharmaceuticals' earnings last quarter?
Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) issued its quarterly earnings data on Tuesday, August, 13th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.46) by $0.05. Crinetics Pharmaceuticals had a negative net margin of 1,303.31% and a negative return on equity of 24.12%. View Crinetics Pharmaceuticals' Earnings History.
When is Crinetics Pharmaceuticals' next earnings date?
What price target have analysts set for CRNX?
3 Wall Street analysts have issued 1-year price objectives for Crinetics Pharmaceuticals' shares. Their forecasts range from $28.00 to $40.00. On average, they anticipate Crinetics Pharmaceuticals' stock price to reach $34.33 in the next twelve months. This suggests a possible upside of 104.9% from the stock's current price. View Analyst Price Targets for Crinetics Pharmaceuticals.
What is the consensus analysts' recommendation for Crinetics Pharmaceuticals?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Crinetics Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Crinetics Pharmaceuticals.
What are Wall Street analysts saying about Crinetics Pharmaceuticals stock?
Here are some recent quotes from research analysts about Crinetics Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Crinetics Pharmaceuticals Inc is a clinical stage pharmaceutical company. It focuses on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's product pipeline consists of CRN00808 for the treatment of Acromegaly, CRN02481 for the treatment of Hyperinsulinemias and CRN01941 for the treatment of Neuroendocrine Tumors which are in clinical stage. Crinetics Pharmaceuticals Inc is based in San Diego, United States. " (10/15/2019)
- 2. HC Wainwright analysts commented, "Valuation; reiterate Buy rating. Our $35 price target for Crinets is based on our sum-of-the-parts NPV valuation based on each of the company’s ongoing products. Our DCF model utilizes a discount rate of 12.2% based on the company’s WACC (Beta of 1.1, equity risk premium of 6.7%)." (4/16/2019)
Has Crinetics Pharmaceuticals been receiving favorable news coverage?
Press coverage about CRNX stock has been trending very negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Crinetics Pharmaceuticals earned a coverage optimism score of -3.2 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Crinetics Pharmaceuticals.
Are investors shorting Crinetics Pharmaceuticals?
Crinetics Pharmaceuticals saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 1,970,000 shares, an increase of 5.3% from the August 30th total of 1,870,000 shares. Based on an average daily trading volume, of 69,200 shares, the short-interest ratio is presently 28.5 days. Currently, 14.2% of the company's stock are sold short. View Crinetics Pharmaceuticals' Current Options Chain.
Who are some of Crinetics Pharmaceuticals' key competitors?
Some companies that are related to Crinetics Pharmaceuticals include Corcept Therapeutics (CORT), Alder Biopharmaceuticals (ALDR), Uniqure (QURE), Tricida (TCDA), Pacira Biosciences (PCRX), Insmed (INSM), Aimmune Therapeutics (AIMT), Heron Therapeutics (HRTX), Nabriva Therapeutics (NBRV), Ironwood Pharmaceuticals (IRWD), Eidos Therapeutics (EIDX), Supernus Pharmaceuticals (SUPN), Madrigal Pharmaceuticals (MDGL), Opko Health (OPK) and BELLUS Health (BLUSF).
What other stocks do shareholders of Crinetics Pharmaceuticals own?
Who are Crinetics Pharmaceuticals' key executives?
Crinetics Pharmaceuticals' management team includes the folowing people:
- Dr. R. Scott Struthers, Founder, Pres, CEO & Director (Age 57)
- Mr. Marc J. C. Wilson, CFO & Sec. (Age 40)
- Dr. Alan S. Krasner, Chief Medical Officer (Age 56)
- Dr. Stephen F. Betz, Co-Founder & VP of Biology (Age 53)
When did Crinetics Pharmaceuticals IPO?
(CRNX) raised $80 million in an initial public offering on Wednesday, July 18th 2018. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray served as the underwriters for the IPO.
How do I buy shares of Crinetics Pharmaceuticals?
Shares of CRNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Crinetics Pharmaceuticals' stock price today?
One share of CRNX stock can currently be purchased for approximately $16.76.
How big of a company is Crinetics Pharmaceuticals?
Crinetics Pharmaceuticals has a market capitalization of $405.59 million and generates $2.43 million in revenue each year. The company earns $-27,110,000.00 in net income (profit) each year or ($2.23) on an earnings per share basis. Crinetics Pharmaceuticals employs 47 workers across the globe.View Additional Information About Crinetics Pharmaceuticals.
What is Crinetics Pharmaceuticals' official website?
How can I contact Crinetics Pharmaceuticals?
Crinetics Pharmaceuticals' mailing address is 10222 Barnes Canyon Road Building #2, San Diego CA, 92121. The company can be reached via phone at 858-450-6464 or via email at [email protected]
MarketBeat Community Rating for Crinetics Pharmaceuticals (NASDAQ CRNX)
MarketBeat's community ratings are surveys of what our community members think about Crinetics Pharmaceuticals and other stocks. Vote "Outperform" if you believe CRNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
